Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, licenses, manufactures, and markets a range of pharmaceutical products globally. Its primary customers include wholesalers, distributors, pharmacies, hospitals, clinics, and government agencies. Revenue is generated from the sale of various products, with significant contributions from drugs like Revlimid (20-25%), Eliquis (15-20%), and Opdivo (10-15%), among others. Factors supporting the company's endurance include a strong pipeline of new drugs and established products, while patent expirations and competition from generic drugs could limit its revenue growth over time.
—
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, licenses, manufactures, and markets a range of pharmaceutical products globally. Its primary customers include wholesalers, distributors, pharmacies, hospitals, clinics, and government agencies. Revenue is generated from the sale of various products, with significant contributions from drugs like Revlimid (20-25%), Eliquis (15-20%), and Opdivo (10-15%), among others. Factors supporting the company's endurance include a strong pipeline of new drugs and established products, while patent expirations and competition from generic drugs could limit its revenue growth over time.
—
Daily adjusted close
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, licenses, manufactures, and markets a range of pharmaceutical products globally. Its primary customers include wholesalers, distributors, pharmacies, hospitals, clinics, and government agencies. Revenue is generated from the sale of various products, with significant contributions from drugs like Revlimid (20-25%), Eliquis (15-20%), and Opdivo (10-15%), among others. Factors supporting the company's endurance include a strong pipeline of new drugs and established products, while patent expirations and competition from generic drugs could limit its revenue growth over time.